157 related articles for article (PubMed ID: 8957091)
41. p53: an overview of over two decades of study.
Cheah PL; Looi LM
Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
[TBL] [Abstract][Full Text] [Related]
42. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
43. Activation of NFAT signal by p53-K120R mutant.
Shinmen N; Koshida T; Kumazawa T; Sato K; Shimada H; Matsutani T; Iwadate Y; Takiguchi M; Hiwasa T
FEBS Lett; 2009 Jun; 583(12):1916-22. PubMed ID: 19416725
[TBL] [Abstract][Full Text] [Related]
44. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
45. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
46. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
47. p53 phosphorylation mutants retain transcription activity.
Fuchs B; O'Connor D; Fallis L; Scheidtmann KH; Lu X
Oncogene; 1995 Feb; 10(4):789-93. PubMed ID: 7862459
[TBL] [Abstract][Full Text] [Related]
48. Tumour suppressor genes and molecular chaperones.
Lane DP; Midgley C; Hupp T
Philos Trans R Soc Lond B Biol Sci; 1993 Mar; 339(1289):369-72; discussion 372-3. PubMed ID: 8493291
[TBL] [Abstract][Full Text] [Related]
49. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
Leiter LM; Chen J; Marathe T; Tanaka M; Dutta A
Oncogene; 1996 Jun; 12(12):2661-8. PubMed ID: 8700525
[TBL] [Abstract][Full Text] [Related]
50. Analysis of p53 binding to DNA by fluorescence imaging microscopy.
Ong HJ; Siau JW; Zhang JB; Hong M; Flotow H; Ghadessy F
Micron; 2012 Sep; 43(9):996-1000. PubMed ID: 22537717
[TBL] [Abstract][Full Text] [Related]
51. Structure-based rescue of common tumor-derived p53 mutants.
Wieczorek AM; Waterman JL; Waterman MJ; Halazonetis TD
Nat Med; 1996 Oct; 2(10):1143-6. PubMed ID: 8837616
[TBL] [Abstract][Full Text] [Related]
52. Regulation of mutant p53 temperature-sensitive DNA binding.
Friedlander P; Legros Y; Soussi T; Prives C
J Biol Chem; 1996 Oct; 271(41):25468-78. PubMed ID: 8810317
[TBL] [Abstract][Full Text] [Related]
53. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
Selivanova G; Iotsova V; Okan I; Fritsche M; Ström M; Groner B; Grafström RC; Wiman KG
Nat Med; 1997 Jun; 3(6):632-8. PubMed ID: 9176489
[TBL] [Abstract][Full Text] [Related]
54. Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA.
Lepre MG; Omar SI; Grasso G; Morbiducci U; Deriu MA; Tuszynski JA
Molecules; 2017 Aug; 22(8):. PubMed ID: 28813011
[TBL] [Abstract][Full Text] [Related]
55. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
[TBL] [Abstract][Full Text] [Related]
56. Mutational analysis of the p53 core domain L1 loop.
Zupnick A; Prives C
J Biol Chem; 2006 Jul; 281(29):20464-73. PubMed ID: 16687402
[TBL] [Abstract][Full Text] [Related]
57. Disarming mutant p53 oncogenic function.
Girardini JE; Marotta C; Del Sal G
Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
[TBL] [Abstract][Full Text] [Related]
58. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
[TBL] [Abstract][Full Text] [Related]
59. P53 mutants suppress ZBP-89 function.
Okada M; Tessier A; Bai L; Merchant JL
Anticancer Res; 2006; 26(3A):2023-8. PubMed ID: 16827139
[TBL] [Abstract][Full Text] [Related]
60. Molecular architecture of tumor suppressor p53.
Viadiu H
Curr Top Med Chem; 2008; 8(15):1327-34. PubMed ID: 18991721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
